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Abstract
Background: Anticoagulation can reduce quality of life, and different models of anticoagulation management might have
different impacts on satisfaction with this component of medical care. Yet, to our knowledge, there are no scales
measuring quality of life and satisfaction with anticoagulation that can be generalized across different models of
anticoagulation management. We describe the development and preliminary validation of such an instrument – the Duke
Anticoagulation Satisfaction Scale (DASS).
Methods: The DASS is a 25-item scale addressing the (a) negative impacts of anticoagulation (limitations, hassles and
burdens); and (b) positive impacts of anticoagulation (confidence, reassurance, satisfaction). Each item has 7 possible
responses. The DASS was administered to 262 patients currently receiving oral anticoagulation. Scales measuring generic
quality of life, satisfaction with medical care, and tendency to provide socially desirable responses were also administered.
Statistical analysis included assessment of item variability, internal consistency (Cronbach's alpha), scale structure (factor
analysis), and correlations between the DASS and demographic variables, clinical characteristics, and scores on the above
scales. A follow-up study of 105 additional patients assessed test-retest reliability.
Results: 220 subjects answered all items. Ceiling and floor effects were modest, and 25 of the 27 proposed items
grouped into 2 factors (positive impacts, negative impacts, this latter factor being potentially subdivided into limitations
versus hassles and burdens). Each factor had a high degree of internal consistency (Cronbach's alpha 0.78–0.91). The
limitations and hassles factors consistently correlated with the SF-36 scales measuring generic quality of life, while the
positive psychological impact scale correlated with age and time on anticoagulation. The intra-class correlation coefficient
for test-retest reliability was 0.80.
Conclusions: The DASS has demonstrated reasonable psychometric properties to date. Further validation is ongoing.
To the degree that dissatisfaction with anticoagulation leads to decreased adherence, poorer INR control, and poor
clinical outcomes, the DASS has the potential to help identify reasons for dissatisfaction (and positive satisfaction), and
thus help to develop interventions to break this cycle. As an instrument designed to be applicable across multiple models
of anticoagulation management, the DASS could be crucial in the scientific comparison between those models of care.
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Background
Oral anticoagulation is indicated for a number of condi-
tions, including prevention of systemic embolism in
patients with mechanical heart valves, valvular heart dis-
ease, myocardial infarction, and atrial fibrillation [1]. It is
often intended that anticoagulation be maintained over
the long term; for example, one of the considerations in
placing a mechanical heart valve is the ability of the
patient to comply with a regimen of anticoagulation for
the remainder of his of her lifetime.
Long-term anticoagulation can be provided in various
fashions; for example, under the direction of a generalist
physician such as an internist, under the direction of a
specialist physician such as a cardiologist, under the direc-
tion of an anticoagulation service managed by a pharma-
cist or nurse, or primarily through patient self-
management. Blood can be obtained for testing using a
vein or a fingerstick, and results can be made available
immediately (using a point-of-care testing device) or can
be provided subsequently through an outside laboratory.
Contact between the provider and the patient can be in-
person, by telephone, by mail, or through the internet.
Regardless of the model of care, there are a number of
characteristics of anticoagulation that can potentially
induce dissatisfaction and reduce quality of life. Among
these characteristics are the need for regular blood testing
and other contacts with the medical system, lifestyle limi-
tations (e.g., restrictions on diet and activities), and possi-
ble worry about bleeding and/or bruising.
Anticoagulation might also have a number of positive
effects; for example, the reassurance provided by effective
treatment and contact with supportive providers.
There are two basic approaches to measuring health-
related quality of life among patients receiving anticoagu-
lation: generic and condition-specific. Generic scales
assess constructs that are common to a wide range of indi-
viduals. For example, the eight subscales of the widely
used SF-36 instrument are physical function, physical
role, bodily pain, general health, vitality, social function,
emotional role, and mental health. Generic instruments
not only facilitate comparisons with other populations
(e.g., between patients undergoing anticoagulation and
those with asthma), but their comprehensiveness can
help identify aspects of the condition under study that
might not have been anticipated by the developers of con-
dition-specific scales.
In contrast to generic scales, condition-specific scales are
intended to be much more narrowly focused toward those
aspects of health-related quality of life that are of the
greatest salience for that condition. For example, an
arthritis-specific scale might include questions about joint
pain, the number of joints that are swollen or tender, and
so forth. Ideally, generic and condition-specific scales can
provide information that is complementary; the former
being broad although not necessarily detailed, and the lat-
ter being detailed but not necessarily broad. The text by
McDowell and Newell provides an excellent introduction
to generic and condition-specific scales, including a
description of various scales such as the SF-36 [2].
There are relatively few extant condition-specific scales
that measure quality of life and satisfaction with anticoag-
ulation, and to our knowledge none of these scales can be
generalized across models of medical care. For research
purposes, having such a scale would be particularly
important in support of studies designed to determine
which approach to anticoagulation management is supe-
rior. In clinical practice, being able to measure quality of
life and satisfaction with anticoagulation management
could help support interventions that increase time in
therapeutic range and reduce adverse thromboembolic or
bleeding events.
Our goal was to develop and validate a scale that could be
administered to anticoagulation patients generally; that
is, across indication for anticoagulation and across mod-
els of anticoagulation management. This report describes
the development and preliminary validation of this scale
– the Duke Anticoagulation Satisfaction Scale (DASS).
Methods
Preliminary studies
We began by identifying various dimensions of anticoag-
ulation-related quality of life, using as sources the litera-
ture, patient focus groups, and expert opinion. The
literature review involved a Medline search, from 1985–
2000, using the terms "anticoagulation" and "quality of
life". The articles resulting from this initial search were
supplemented by a review of their bibliographies, a review
of the reports from various large randomized trials of
warfarin, and a hand-review of the Archives of Internal
Medicine (this journal being particularly noteworthy for
its attention to issues of anticoagulation) from 1985–
2000 [3-9].
After Institutional Review Board approval, two patient
focus groups were organized to help identify the domains
of interest and also to record the phrasing of the patients'
comments (so as to reflect this phrasing, if possible, in the
actual wording of the DASS items). Patients were recruited
from local anticoagulation services. A majority of these
patients had undergone anticoagulation for an extended
period of time.
We conducted initial interviews with five experts (a physi-
cian assistant, a pharmacist, and three physicians, all ofHealth and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/22
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whom are widely experienced in anticoagulation prac-
tice), then asked these experts to comment on the pro-
posed dimensions and item wording.
Once a preliminary set of items was developed, we admin-
istered an initial draft of the instrument in "talk-through
interviews" with nine patients. Items were modified, and
the process was repeated with another set of nine patients.
We then administered the resulting 26-item instrument to
122 patients in the Duke anticoagulation service. Of
these, 105 had a single interview, and 17 also had a sec-
ond interview approximately one month later. The results
of this study were examined: (a) at the item level, with fre-
quency distributions, means and standard deviations; and
(b) at the scale level, in order to determine which items
seemed to group together. Briefly, most items had suffi-
cient variation and grouped into the expected dimen-
sions. Five to seven items did not, and were thus the
strongest candidates for deletion or revision.
To create the current version of the DASS, the above ver-
sion was revised, paying particular attention to the items
that had performed poorly in the previous study. In addi-
tion, the wording of the items was reviewed by a linguistic
consultant, in order to help simplify the instrument as
much as possible.
Description of the DASS
The resulting 27 items, 25 of which are included in the
final version of the DASS, are provided in Additional file:
1. All items have seven response categories: "not at all", "a
little", "somewhat", "moderately", "quite a bit", "a lot",
and "very much". The pattern of the questions is arranged
to roughly correspond to three possible dimensions per-
taining to anticoagulation: limitations (e.g., limitations on
physical activities due to fear of bleeding, dietary restric-
tions); hassles and burdens (e.g., both daily hassles such as
remembering to take the medicine, as well as occasional
hassles such as having to wait while visiting a provider for
blood testing), and positive psychological impacts (e.g., reas-
surance because of anticoagulation treatment).
Item content in the DASS varies from specific (e.g., "How
much does the possibility of bleeding or bruising limit
you from taking part in physical activities?") to general
(e.g., "Overall, how much does the possibility of bleeding
or bruising affect your daily life?"). A few items (e.g.,
"How much does anti-clot treatment limit the alcoholic
beverages you might wish to drink?") apply to a subset of
patients (e.g., those that consume alcohol); when an item
does not apply, the patient is requested to answer "not at
all".
Validation study design
The above 27-item version of the DASS was administered
to 262 patients, 125 of whom were managed by a physi-
cian assistant in an anticoagulation service within the
Department of Veterans Affairs, and 137 of whom were
managed by physicians in general community practices.
In addition to the DASS, we recorded various demo-
graphic and clinical characteristics (table 1) as well as
three other scales: the SF-36 (generic quality of life), the
PSQ-18 (satisfaction with medical care), and the SDS-5
(tendency to give socially desirable responses) [10,11].
Two of the above 27 items were subsequently dropped,
yielding a final instrument containing 25 items.
We then performed an additional study in order to assess
the test-retest reliability of the final 25-item version of the
DASS. For this study, 105 subjects were surveyed approxi-
mately 7–14 days apart, 103 of whom completed both
interviews and are included in the analysis. One item
("Overall, how much has anti-clot treatment had a nega-
tive impact on your life?") was inadvertently excluded
from the instrument.
Analysis
The statistical analysis began with assessment of the pat-
tern of missing values among the DASS items. Among
patients that completed all the DASS items, we then
assessed the degree of variability among individual items
using frequency distributions, means and standard devia-
tions. In order to assess internal consistency, we then
examined the factor structure of the DASS, using the tech-
niques of exploratory factor analysis with orthogonal rota-
tions. Cronbach's alpha and item-total correlations were
calculated for the overall DASS, treating the scale as a sim-
ple summation of the items, and also for its various pos-
sible subscales. Finally, in order to assess concurrent
validity both the summated DASS scale score, as well as its
subscales, were correlated with demographic variables,
clinical characteristics, and scores on the above scales.
Test-retest reliability, as applied to the overall summated
DASS score, was assessed using the intra-class correlation
coefficient, and also by summary statistics (mean, stand-
ard deviation) describing the differences between the
DASS scores at the two time periods. The items from the
first time point in the test-retest study were also used as
inputs into a confirmatory factor analysis.
For consistency of presentation, all analyses involved first
reverse-coding six items, as noted in the legend of Addi-
tional file: 1. (After this reverse-coding, for all items lower
scores indicate greater satisfaction.)
Results
Table 1 describes the demographic and clinical character-
istics of the subjects. A typical subject was a married whiteHealth and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/22
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male, aged 69 years, having been receiving anticoagula-
tion for over 4 years and taking multiple medications.
Approximately three quarters of the sample completed
high school. Various indications for anticoagulation were
represented, of which atrial fibrillation was the most com-
mon (57%). Table 1 also presents the results of the co-
administered scales. Of particular note, the SF-36 scales
describing physical functioning were lower than those
describing social functioning. The SDS-5 scores showed
that the subjects had a tendency to give socially desirable
responses; the PSQ-18 indicated generally high satisfac-
tion with the medical care system as a whole.
Table 1: Demographic characteristics, clinical characteristics, co-administered scales
Age (mean, standard deviation) 68.70 (12.34)
Years on coumadin 4.40 (4.94)
Number of medications 6.45 (4.47)
How survey completed (%)
On own 71
Asked questions 9
Read to respondent 20
Male gender (%) 76
White race (%) 78
Currently married (%) 68
Education (%)
Grade school or some high school 23
High school 29
Some college 21
Completed college 26
Money to pay the bills (%)
More than enough 44
Just enough 41
Not enough 15
Currently working for pay (%) 22
More than one dose change last year (%) 63
Hospitalized for bleeding last year (%) 5
Taken antibiotics last month (%) 22
Blood drawn (%)
Fingerstick 14
Vein 82
Both 4
Self-reported medical history (%)
Atrial fibrillation 57
Stroke 18
Transient ischemic attack 18
Myocardial infarction 25
Deep vein thrombosis 17
Mechanical heart valve 17
Uses pillbox to track medicines (%) 58
Emotional distress last 5 years (%) 14
SDS-5 20.29 (3.21)
PSQ-18 40.37 (8.89)
SF-36
Physical function 52.82 (30.58)
Physical role 45.29 (42.35)
Bodily pain 60.84 (23.39)
General health 53.30 (16.48)
Vitality 51.80 (23.49)
Social function 75.90 (26.67)
Emotional role 71.28 (39.96)
Mental health 76.13 (18.09)
The SF-36 is scored on a 0–100 scale, with higher scores indicating better functioning. The PSQ-18 is scored on a 18–90 scale, with higher scores 
indicating greater satisfaction with medical care. The SDS-5 is scored on a 5–25 scale, with higher scores indicating greater tendency to provide 
socially desirable responses.Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/22
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Table 2 summarizes the DASS data at the level of the item.
Of 262 subjects, 1 did not fill out any of the DASS items,
41 had at least one missing item, and 220 had complete
data on the DASS. The items most commonly left missing
pertained to work limitations, alcohol limitations, overall
positive impact and, to a lesser extent, overall confidence,
difficulty in managing anticoagulation, and whether the
subject would recommend their current model of antico-
agulation to others. We believe it is likely that that, for the
questions about work and alcohol limitations, most of
those with missing responses did not drink alcohol or
were not currently working, and failed follow the direc-
tions to answer "not at all" under those circumstances.
Based on the talk-through interviews, the other items
listed above tended to be those which at least some
respondents had difficulty in conceptualization. All items
evidenced a noteworthy degree of variation (e.g., standard
deviations of approximately one unit or more).
Tables 3 and 4 present a summary of the factor analysis.
The six eigenvalues exceeding unity were 8.73, 3.25, 1.66,
1.43, 1.16, and 1.04. These latter two eigenvalues were
close to unity, suggesting that no more than four factors
should be considered.
Accordingly, rotated factor solutions were fit with 2, 3 and
4 factors. The 4-factor solution had inconsistent loadings
(i.e., multiple items loaded on more than one factor), and
is not considered further. The two items pertaining to
"worry about anti-clot treatment" and "worry about the
bad things anti-clot treatment is intended to prevent" had
inconsistent loadings in the 3-factor solution, and were
dropped. (In part, this decision was made because these
items addressed a different construct than other items in
the limitations, hassles and burdens factor(s) on which
they would have been placed. In the 2-factor solution, the
two items in question clearly loaded onto the "negative
impacts" scale.)
Considering the 2-factor solution, 24 of the 25 items
showed "simple structure" by having the rotated factor
loading exceed 0.40 for only one of the factors. The only
exception was the item pertaining to alcohol, which had a
loading of only 0.26, perhaps because of the difficulties
induced by having large numbers of patients respond "not
Table 2: DASS Item-level summary statistics
I t e m 1234567M e a n s . d . M i s s
1 a1 3 4 4 31 21 41 14 2 1 . 8 4 1 . 3 7 3
1 b 1 8 4 1 7 744401 . 3 6 0 . 9 9 3
1c 154 33 7 12 6 4 4 1.69 1.36 4
1 d 1 6 7 1 4 75681 3 1 . 8 4 1 . 7 8 1 4
1 e 1 1 6 6 1 2 2 85441 . 8 8 1 . 3 1 2
2a 75 54 35 15 25 12 4 2.60 1.66 0
2 b 1 6 0 1 3 1 1 6591 6 1 . 9 7 1 . 8 9 8
2c 75 39 37 14 14 12 29 3.02 2.12 1
2d 89 67 27 19 10 3 5 2.20 1.43 3
3a 123 62 15 10 4 3 3 1.78 1.22 1
3b 86 78 25 18 8 4 1 2.09 1.25 0
3 c 1 3 5 5 4 1 5 86021 . 6 5 1 . 0 9 0
3d 108 80 14 13 5 0 0 1.76 0.97 3
3 e 1 2 8 5 7 1 5 95331 . 7 6 1 . 2 4 3
3 f 1 7 1 3 3 751211 . 3 7 0 . 9 0 4
3g 109 78 15 10 2 3 3 1.81 1.17 3
3h 87 42 25 14 5 17 30 2.90 2.19 6
4 a1 0 2 4 23 21 61 28 8 2 . 3 2 1 . 6 7 3
4b 62 55 33 32 20 13 5 2.78 1.66 4
4d 70 66 33 20 13 10 8 2.55 1.64 3
4f 29 27 43 24 19 37 41 4.15 2.08 8
4g 106 63 20 18 6 4 3 2.00 1.34 4
4h 84 38 33 37 19 4 5 2.55 1.60 4
4i 132 53 12 14 2 5 2 1.75 1.23 6
4j 99 35 36 25 8 4 13 2.42 1.73 6
See additional file 1 for item descriptions. Items 3h, 4a, 4b, 4f, 4h and 4j have been reverse coded. Items 4c and 4e were deleted. The first 7 columns 
give the frequencies of each of the 7 response categories (after reverse-coding, as appropriate). Column 10 gives the number (out of 261 subjects 
with responses to at least 1 DASS item) of subjects with a missing response to the item in question.Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/22
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at all". All items grouped onto their anticipated factors.
The variance explained by the "negative" and "positive"
factors was 7.97 (32% of 25) and 3.22 (13% of 25),
respectively.
Considering the 3-factor solution, the anticipated group-
ing of items into the factors of "limitations", "hassles",
and "positive impacts" was observed; in essence, the items
in the "negative" factor in the 2-factor model were disag-
gregated into two sub-factors. This delineation was rea-
sonably consistent, albeit not always completely clear-cut;
for example, the item asking about the hassle of the daily
anti-coagulation related tasks had a rotated factor loading
of 0.60 onto "hassles" and 0.51 onto "limitations". The
variance explained by the hassles, limitations and positive
impact factors was 5.05, 4,82 and 2.96, respectively.
The various Cronbach's alpha coefficients were as follows:
0.88 for the overall DASS summary score, 0.78 for the pos-
itive impact sub-scale, 0.91 for the negative impact sub-
scale, 0.87 for the limitations sub-scale, and 0.88 for the
hassles sub-scale.
In the confirmatory factor analysis on the test-retest sam-
ple, the original 2-factor solution was replicated, to a
notably high degree of fidelity (data not shown). The
results of the 3-factor solution were roughly similar to the
previous factor analysis in the sense that all of the six
items from the positive impact sub-scale were as before,
and that most of the negative items disaggregated them-
selves into two other scales. The placement of items into
the "hassles" versus "limitations" factors was mostly, but
not entirely, consistent with the results of the previous fac-
tor analysis. However, simple structure was not main-
tained, as some items appeared to load onto both the
"hassles" and "limitations" factors.
Table 5 reports correlations between the DASS summary
scale, its sub-scales, and various subject characteristics and
co-administered scales. The overall DASS score, the nega-
tive impacts sub-scale, the hassles sub-scale, and the limi-
tations sub-scale behaved similarly; in particular, these
were consistently correlated with the sub-scales of the SF-
36. Also, these scales were positively correlated with the
experience of being hospitalized for bleeding during the
last year and of having more than one dosage adjustment
during that period of time. The positive impact sub-scale
Table 3: DASS factor analysis results: 2-factor solution
Item Loading: Negative Loading: Positive Communality New alpha Item-total
1a 0.72 -0.16 0.54 0.91 0.66
1b 0.68 -0.14 0.48 0.91 0.63
1c 0.41 -0.15 0.19 0.92 0.37
1d 0.63 -0.29 0.48 0.91 0.56
1e 0.79 -0.20 0.66 0.91 0.72
2a 0.62 -0.21 0.43 0.91 0.56
2b 0.26 -0.09 0.07 0.92 0.24
2c 0.49 -0.11 0.26 0.91 0.46
2d 0.82 -0.11 0.68 0.91 0.77
4d 0.67 0.01 0.46 0.91 0.63
3a 0.79 0.02 0.62 0.91 0.74
3b 0.70 0.15 0.52 0.91 0.61
3c 0.59 0.21 0.39 0.91 0.53
3d 0.69 0.11 0.49 0.91 0.64
3e 0.67 0.20 0.48 0.91 0.61
3f 0.51 0.11 0.26 0.91 0.45
3g 0.69 0.20 0.53 0.91 0.64
4g 0.66 0.13 0.45 0.91 0.61
4i 0.54 0.23 0.34 0.91 0.47
3h -0.10 0.41 0.17 0.80 0.33
4a -0.01 0.66 0.43 0.74 0.57
4b 0.08 0.79 0.63 0.71 0.70
p4f -0.24 0.57 0.38 0.78 0.42
4h 0.25 0.79 0.69 0.73 0.62
4j 0.03 0.74 0.55 0.74 0.58
The elements are rotated factor loadings (columns 2–3), communalities (column 4), Cronbach's alpha coefficient with the item in question deleted, 
calculated using standardized variables (column 5), and the item-total correlation, calculated using standardized variables (column 6).Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/22
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was less strongly correlated with the other quality-of-life
measures, although it was more strongly correlated with
age and time on anticoagulation.
The 103 subjects used in the test-retest study were similar
to those of the main study for the SF-36 scales and most
demographic characteristics (data not shown). By way of
exception, the test-retest subjects were more likely to be
female (38%) and to have completed high school (93%).
Approximately 91% reported no significant changes in
health between the two interviews. The mean DASS scores
(standard deviation in parentheses) were 53.4 (17.6) and
54.9 (18.9) at interviews 1 and 2, respectively. Table 6
describes the distribution of the difference scores
summarizing the changes in the DASS over the approxi-
mately 2-week period between measurements. The major-
ity of scores were within 10 units of the initial score, and
the intra-class correlation coefficient (estimated from a
random effects model using subject, visit and error) was
0.80.
Discussion
We have described the development and preliminary val-
idation of the DASS, a scale to measure satisfaction and
quality of life with anticoagulation. Individual DASS
items showed sufficient variation, and the large majority
of items clearly grouped into scales reflecting positive and
negative impacts of anticoagulation. This latter scale can,
if desired, be further sub-divided into sub-scales reflecting
limitations imposed by anticoagulation versus the hassles
and burdens of anticoagulation management. The inter-
nal consistency of the overall scale is good (Cronbach's
alpha 0.88), with the sub-scales falling into a similar
range (alpha 0.78 to 0.91). The sub-scales correlate with
various measures of health status and satisfaction with
medical care. The level of variation from test to test (intra-
class correlation 0.80) is higher than the ideal, but
acceptable.
Although these initial results appear promising, various
limitations should be noted. Validation is a multi-step
process, requiring numerous positive findings, across a
variety of applications, before a scale can be invested with
full confidence. Some natural follow-up studies would
include, among others, administration across a broader
cross-section of patients. The DASS does not yet have
norms to quantify, for example, clinically significant dif-
Table 4: DASS factor analysis results: 3-factor solution
Item Loading: Limits Loading: Hassles Loading: Positive Communality New alpha Item-total
1a 0.68 0.34 -0.07 0.58 0.85 0.67
1b 0.67 0.30 -0.04 0.54 0.85 0.65
1c 0.50 0.09 -0.04 0.26 0.87 0.40
1d 0.77 0.13 -0.12 0.63 0.85 0.65
1e 0.81 0.31 -0.06 0.76 0.84 0.77
2a 0.56 0.32 -0.16 0.44 0.86 0.56
2b 0.43 -0.06 0.06 0.19 0.88 0.31
2c 0.48 0.22 -0.04 0.28 0.87 0.48
2d 0.75 0.41 -0.02 0.73 0.84 0.78
4d 0.58 0.38 0.07 0.49 0.86 0.60
3a 0.51 0.60 -0.01 0.62 0.87 0.69
3b 0.34 0.65 0.06 0.54 0.87 0.64
3c 0.19 0.64 0.08 0.46 0.87 0.59
3d 0.26 0.71 -0.02 0.58 0.87 0.68
3e 0.12 0.81 0.00 0.67 0.86 0.74
3f 0.27 0.44 -0.05 0.27 0.88 0.46
3g 0.20 0.77 0.06 0.64 0.86 0.74
4g 0.29 0.64 0.03 0.49 0.87 0.58
4i 0.07 0.68 0.06 0.47 0.88 0.56
3h 0.04 -0.17 0.51 0.29 0.80 0.33
4a 0.06 -0.06 0.76 0.58 0.74 0.57
4b 0.01 0.11 0.83 0.70 0.71 0.70
4f -0.25 -0.07 0.57 0.39 0.78 0.42
4h -0.02 0.38 0.74 0.69 0.73 0.67
4j -0.15 0.20 0.70 0.56 0.74 0.58
The elements are rotated factor loadings (columns 1–3), communalities (column 4), Cronbach's alpha coefficient with the item in question deleted, 
calculated using standardized variables (column 5), and the item-total correlation, calculated using standardized variables (column 6).Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/22
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ferences in quality of life, although generic methods
might be used as at least a first approximation [12].
Another limitation pertains to the definition of the sub-
scales. Although the overall pattern of the data was con-
sistent with the ideal of simple structure, some items did
load onto their respective sub-scales less strongly than
others. For some items, this might reflect a moderate ceil-
ing effect. In other cases, this might reflect a tendency for
different respondents to conceptualize these items differ-
ently. The willingness to accept differing interpretations of
the various items was consistent with the philosophy
under which the DASS was developed; namely, that in
order to be relevant to individual patients and extendable
across a wide variety of applications, the scale should
address its constructs as generically as possible.
How best to conceptualize quality of life associated with
anticoagulation management was an ongoing challenge
during the scale development process, a particular diffi-
culty being that our experts (as well as the literature)
tended to make somewhat finer distinctions (e.g.,
between limitations versus hassles and burdens) than
were typically made by patients. Our solution was to
structure the instrument with into separate sets of ques-
tions representing these fine distinctions (e.g., "limita-
tions" comprising one such set), but to retain the option
of combining the items in these sets into more general
sub-scales. When applying the DASS to other models of
anticoagulation management, the questions themselves
could be retained (e.g., as they were designed to be appli-
cable across models of care), but some of the text in their
stems might be changed. For example, the list of possible
daily and occasional tasks would likely differ according to
the model of care.
The primary decision for the user that wishes to apply the
DASS at the level of the sub-scale is whether to break the
Table 5: Correlation with DASS total score and subscales
Total Negative impact Limitations Hassles Positive impact
Age -0.17 * -0.27** -0.24** -0.24** 0.19**
Years on coumadin -0.05 0.01 0.01 0.01 -0.14*
<3 months on coumadin 0.04 -0.05 -0.05 -0.03 0.19**
Number of medications 0.00 0.02 0.05 -0.03 -0.04
Completed survey alone 0.14 0.17* 0.18** 0.12 -0.05
Male -0.08 -0.06 -0.03 -0.09 -0.05
White -0.12 -0.15* -0.18 -0.08 0.05
HS education 0.03 0.11 0.10 0.10 -0.16*
Low income 0.12 0.09 0.10 0.05 0.08
Work for pay 0.01 0.02 -0.02 0.07 -0.01
Dose change last year 0.18** 0.20** 0.18** 0.19** -0.01
Hospitalized for bleed 0.19** 0.22** 0.23** 0.16* -0.04
Antibiotics last month 0.00 -0.02 0.01 -0.6 0.06
Fingerstick 0.05 0.01 0.00 0.03 0.09
Atrial fibrillation 0.00 -0.03 -0.05 0.00 0.07
Stroke 0.19** 0.20** 0.14 0.22** 0.02
T I A 0 . 1 20 . 1 20 . 0 60 . 1 6 * 0 . 0 4
Myocardial infarction 0.02 0.08 0.08 0.06 -0.12
DVT 0.00 0.09 0.11 0.04 -0.18**
Mechanical heart valve 0.06 0.11 0.10 0.10 -0.10
Pillbox 0.11 0.14 0.14* 0.10 -0.02
Emotional distress 0.21** 0.21** 0.17 0.22** 0.04
PSQ-18 0.19** 0.07 0.01 0.15* 0.28**
SF-36 physical function -0.23** -0.18** -0.20** -0.11 -0.16*
SF-36 physical role -0.31** -0.28** -0.28** -0.21** -0.12
SF-36 bodily pain -0.27** -0.26** -0.27** -0.19** -0.08
SF-36 general health -0.17** -0.23** -0.20** -0.21** 0.09
SF-36 vitality 0.28** 0.27** 0.26** 0.23** 0.07
SF-36 social function -0.40** -0.39** -0.36** -0.35** -0.09
SF-36 emotional role -0.32** -0.28** -0.24** -0.27** -0.14*
SF-36 mental health -0.40** -0.39** -0.29** -0.45** -0.09
Mean(std) 54.0 (17.6) 36.9 (16.1) 20.9 (10.4) 16.0 (7.5) 17.1 (7.5)
One asterisk denotes p < .05, 2 asterisks denote p < .01.Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/22
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"negative impact" scale into two component parts. As dis-
cussed above, the structure of the instrument and, indeed,
our original expectations regarding the factor analysis,
was based on the notion that the negative impact scale
would be sub-divided. However, both the original factor
analysis and a subsequent confirmatory factor analysis
showed somewhat stronger support for the simpler model
including positive and negative factors only. The size of
the test-retest sample (i.e., 103 subjects) was near the
lower limit for a factor analysis, so we do not interpret this
confirmatory factor analysis as definitive; nevertheless, its
conclusions were quite similar to those of the original fac-
tor analysis. Taken as a whole, our interpretation is that a
2-factor solution may be the most natural, but that a user
with a specific need to utilize three factors could reasona-
bly do so. The current comparison between the 2- and 3-
factor solutions is not definitive and, indeed, it is quite
conceivable that choice of sub-scale could differ according
to the patient population or the model of anticoagulation
management under study.
When considering the sub-scales, the internal consistency,
as measured by Cronbach's alpha, approached 0.90 for
the negative impacts, hassles and limitations sub-scales,
but was closer to 0.80 for the positive impact scale. The
lower figure for the positive impact sub-scale might in part
be a result of the number of items (i.e., on average, the
more items the higher the alpha coefficient), but also
because the items address a construct that is broader, and
perhaps more subject to individual interpretation, than is
the case for the items pertaining to the negative impact of
anticoagulation. Authorities disagree on the precise
benchmarks that should be applied to psychometric
measures such as alpha coefficients (these benchmarks in
part depending on the application; for example, with
lower correlations being acceptable for scales that are
intended to compare groups than for scales use to meas-
ure change within individuals). Nevertheless, the internal
consistency evidenced by the DASS, both in terms of the
rotated factor loadings and the Cronbach's alpha coeffi-
cients of its sub-scales, is quite consistent with usual prac-
tice for measures that are intended to be used at the level
of the group. A similar interpretation applies to the test-
retest analysis.
A final challenge in the item development process
involved the strong socialization of patients undergoing
long-term anticoagulation. Often, patients have been
informed that long-term anticoagulation is a medical
necessity, without an equally good alternative. (One of
the conditions for receiving a heart valve is acceptance of
anticoagulation for the remainder of the patient's life. In
other circumstances, such as atrial fibrillation, alternatives
such as aspirin that are less burdensome yet less effective
are available, thus implying that patients that receive
anticoagulation have self-selected, at least initially, as per-
ceiving the burdens of this therapy as being less than its
benefits.) Any life style modifications (such as eliminating
activities likely to result in bleeding and bruising)
required by this therapy may have been made long ago,
and the effects of these modifications, although initially
distressing, may no longer be considered by the patient as
reducing quality of life. Nevertheless, it is quite reasonable
to speculate that if the patient were managed using a less
burdensome model of care, perceived quality of life
would improve. Some of the final items in the DASS (e.g.,
whether the patient would recommend this form of anti-
coagulation) are an attempt to address this issue, but our
talk-through interviews suggested that a non-trivial
number of patients found such an exercise in visualization
to be conceptually difficult. We know of no ideal solution
to this problem, which is by no means limited to the
present application.
The clinical relevance of the DASS lies in its ability to sum-
marize satisfaction with anticoagulation and in particular
to help identify aspects of anticoagulation that may
hinder individual patients from maintaining a PT-INR
within therapeutic range. Some of these aspects might be
amenable to direct intervention; for example, those
patients that find anticoagulation management to be
extraordinarily complicated might benefit from either
additional anticoagulation-related education, or perhaps
from a mode of management that requires less regular
testing. Other aspects might not be as directly amenable.
For example, those patients who had experienced an out-
come such as hospitalization for bleeding or multiple
dosage changes during the past year also tended to report
higher scores for hassles and limitations; in effect, becom-
ing more sensitized to anticoagulation's potentially nega-
tive aspects. However, even in the absence of a more direct
Table 6: Difference Scores on Re-administration, Approximately 
Two Weeks Apart
Difference score (t2-t1) Frequency
<= -21 2
-16 to -20 3
-15 to -11 9
-10 to -6 16
-5 to -1 16
01
1 to 5 20
6 to 10 15
11 to 15 14
16 to 20 1
> = 21 6Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/22
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intervention, providers might at least maintain increased
vigilance for such patients.
In this spirit, providers need not only focus on the nega-
tive aspects of anticoagulation, but might also choose to
especially reinforce those positive aspects that are consid-
ered to be particularly salient by each individual patient.
In any event, the ultimate goal is that from identifying the
limitations, hassles and burdens, and positive psycholog-
ical impacts experienced by patients, the cycle of dissatis-
faction, leading to poor adherence, leading to poor INR
control, leading to poor clinical outcomes, can be broken.
The scientific relevance of the DASS is that when interven-
tions to break this cycle are designed, a standard of com-
parison will be required that is applicable across all the
models of care being compared. Our intention is that the
DASS can help provide a way forward in developing such
a standard. Additional research is needed in order to bet-
ter understand the relationship between anticoagulation-
related quality of life and adherence to treatment regi-
mens, as well as how these regimens can be improved.
Conclusion
Using the DASS we were able to identify less-than-com-
plete satisfaction among outpatients receiving anticoagu-
lation. An initial psychometric analysis of the statistical
properties of the DASS is encouraging. The clinical rele-
vance of the DASS lies in its ability to summarize satisfac-
tion with anticoagulation and to identify aspects of
anticoagulation that may hinder individual patients from
maintaining a PT-INR within therapeutic range. From
identifying the limitations, hassles and burdens, and pos-
itive psychological impacts experienced by patients, many
interventions can potentially be designed to improve anti-
coagulation quality of care, and thus reduce the time
spent outside therapeutic range and, ultimately, thromo-
embolic and bleeding events. The scientific relevance of
the DASS is that when such interventions are designed, a
standard of comparison will be required that is applicable
across all the models of care being compared. Our inten-
tion is that the DASS can help provide a way forward in
developing such a standard. Recognizing that instrument
development and validation is by no means a one-time
event, efforts at assessing and improving the DASS are
ongoing.
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